Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0% · short 0.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ARYx Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
10 buys6 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| KRAMLICH C RICHARDtrack record | Sell | $312.8K | SEC | ||
| DRANT RYAN Dtrack record |
| Sell |
| $312.8K |
| SEC |
| KOLLURI KRISHNA KITTUtrack record | Sell | $312.8K | SEC |
| KERINS PATRICK Jtrack record | Sell | $312.8K | SEC |
| BASKETT FORESTtrack record | Sell | $312.8K | SEC |
| HENNER DENNIS | BuyD (derivative) | $5K | ClusterFirst in 12mo | SEC |
| SIMON NICHOLAS J IIItrack record | BuyD (derivative) | $5K | Cluster | SEC |
| MPM BIOVENTURES III PARALLEL FUND, LPtrack record | BuyD (derivative) | $5K | ClusterFirst in 12mo | SEC |
| GADICKE ANSBERTtrack record | BuyD (derivative) | $5K | ClusterFirst in 12mo | SEC |
| MPM BIOVENTURES III GP LPtrack record | BuyD (derivative) | $5K | ClusterFirst in 12mo | SEC |
| SIMON NICHOLAS J IIItrack record | BuyD (derivative) | $5K | ClusterFirst in 12mo | SEC |
| BEIER DAVID W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SIMON NICHOLAS J IIItrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Leonard Keith R | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ROSENMAN HERM | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SEKHRI PAUL Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ekman Lars | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Barker Jason | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagler David | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Milner Peter G | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Druzgala Pascal | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Varian John | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GODDARD PAUL | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagler David | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Nagler David | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |